Kareem Mosaheb
YOU?
Author Swipe
View article: Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma
Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma Open
Introduction: Depth of response after idecabtagene vicleucel (ide-cel) CAR-T cell therapy has been correlated with longer progression-free survival in patients (pts) with relapsed or refractory multiple myeloma (R/R MM). BCMA-targeted bisp…